Sagimet Biosciences Inc. Series A Common Stock (SGMT)
Stock · NASDAQ · Health Care
$8.03as of 10/16/2026
Price chart
Active signals
Support level
$6.95
Industry
Biotechnology: Pharmaceutical Preparations
SGMT Signal Track Record
How signals performed across all stocks →What SGMT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 20 | +2.2% | 50% | September 18, 2026 |
| Bollinger Band Breakdown | 11 | +4.9% | 64% | September 24, 2026 |
| Bollinger Band Breakout | 12 | -3.6% | 42% | August 5, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -8.1% | 17% | June 8, 2026 |
| Any 20-session window (baseline) | -0.4% | 48% |
Computed by MarketWall from daily closing prices since April 29, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated stea…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 16
- Website
- sagimet.com/
Fundamentals
- 1-day range
- $7.94$8.25
- Market cap
- $539.71M
- P/E (trailing)
- —
- P/E (forward)
- -6.17
- EPS (trailing)
- $-1.28
- Dividend yield
- —
- Beta
- 3.54
- Avg. volume
- 1.27M
52-week range
$4.5$11.45
Next earnings: November 12, 2026 · EPS estimate $-0.26Before Openconfirmed
Forecasts
11 analyst ratings
Buy 89%
Hold 11%
Sell 0%
1-year price forecast
High
$56
+597.4%
Median
$27
+236.2%
Low
$7
-12.8%
Sagimet Biosciences Inc. Series A Common Stock Competitors
Chosen by industry and closest market cap.
- SGMTSagimet Biosciences Inc. Series A Common Stock$8.02▼ 1.84%Market cap $539.71MP/E —$4.5$11.45
- SLNSilence Therapeutics Plc American Depository Share$8.68▼ 7.17%Market cap $548.50MP/E —$1.06$5.99
- STTKShattuck Labs Inc. Common Stock$5.42▼ 1.99%Market cap $549.03MP/E —$1.7$8.33
- SPRYARS Pharmaceuticals Inc. Common Stock$4.02▼ 1.23%Market cap $551.13MP/E —$3.89$13.15
- VSTMVerastem Inc. Common Stock$8.65▼ 6.28%Market cap $519.33MP/E —$3.43$10.82
- RLMDRelmada Therapeutics Inc. Common Stock$3.1▼ 3.13%Market cap $563.26MP/E —$1.8$8
- ARVNArvinas Inc. Common Stock$6.97▼ 2.65%Market cap $567.55MP/E 50.48$6.74$14.51
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SGMT Sagimet Biosciences Inc. Series A Common Stock | $539.71M | — | $8.02 | ▼ 1.84% | $4.5$11.45 |
| SLN Silence Therapeutics Plc American Depository Share | $548.50M | — | $8.68 | ▼ 7.17% | $1.06$5.99 |
| STTK Shattuck Labs Inc. Common Stock | $549.03M | — | $5.42 | ▼ 1.99% | $1.7$8.33 |
| SPRY ARS Pharmaceuticals Inc. Common Stock | $551.13M | — | $4.02 | ▼ 1.23% | $3.89$13.15 |
| VSTM Verastem Inc. Common Stock | $519.33M | — | $8.65 | ▼ 6.28% | $3.43$10.82 |
| RLMD Relmada Therapeutics Inc. Common Stock | $563.26M | — | $3.1 | ▼ 3.13% | $1.8$8 |
| ARVN Arvinas Inc. Common Stock | $567.55M | 50.48 | $6.97 | ▼ 2.65% | $6.74$14.51 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Sagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China TrialYahoo · 10/9/2026
- Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11benzinga · 10/9/2026
- Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology ConferenceYahoo · 10/9/2026
- Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11Benzinga · 10/9/2026
- HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price TargetBenzinga · 10/5/2026
- Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial LaunchYahoo · 10/4/2026
- Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26Benzinga · 10/2/2026
- Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded WarrantsYahoo · 10/1/2026
- Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38Benzinga · 10/1/2026
Insider Activity
Insider Actions →Acquired
608.6K
Disposed
464.6K
- George Kemble · August 14, 2026 · Option Exercise24.4K @ $6.36
- George Kemble · August 14, 2026 · Option Exercise326.6K @ $6.36
- George Kemble · August 14, 2026 · Sale351.0K @ $10.23
- George Kemble · August 11, 2026 · Option Exercise10.5K @ $6.36
- George Kemble · August 11, 2026 · Option Exercise9.8K @ $6.36
- George Kemble · August 11, 2026 · Sale20.2K @ $9.95
- David Happel · July 20, 2026 · Sale64.1K @ $7.76
- Elizabeth Rozek · July 20, 2026 · Sale10.5K @ $7.76
- George Kemble · July 20, 2026 · Sale18.8K @ $7.46
- Hoelscher Paul W. · June 12, 2026 · Grant39.6K
- Jennifer Jarrett · June 12, 2026 · Grant39.6K
- George Kemble · June 12, 2026 · Grant39.6K
- Phillips Anne M. · June 12, 2026 · Grant39.6K
- GRAMMER ELIZABETH A · June 12, 2026 · Grant39.6K
- Beth C. Seidenberg · June 12, 2026 · Grant39.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 13.59M
- Total value held
- $69.85M
- Institutional holders
- 84
Top holders this quarter
- Unknown1.10M
- Unknown1.00M
- Unknown966.3K
- Unknown953.0K
- Unknown868.0K
- Unknown862.3K
- Unknown799.9K
- Unknown724.8K
- Unknown625.5K
- Unknown411.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Goldman Sachs reinstates Sell rating on SGMT with $7 target
Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.
Goldman Sachs reinstates Sell rating on SGMT with $7 target. Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.